Abstract
Gemcitabine is one of the recently developed drugs with a high efficacy in various malignant tumours and a mild toxicity profile. As monochemotherapy in metastatic breast cancer, gemcitabine yielded response rates up to 46% as first- and second-line treatment. Neutropenia is the clinically most relevant unwanted effect. Haematological and nonhaematological toxicities are mild, making dose reductions, delays of treatment or withdrawal from treatment very rare. The first phase I and phase II studies of gemcitabine in combination with anthracyclines have shown a good toxicity profile and promising remission rates. Phase I experiences with long-time infusion schedules reveal good feasibility and high patient acceptance.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 5 March 1998 / Accepted: 15 July 1998
Rights and permissions
About this article
Cite this article
Lüftner, D., Flath, B., Akrivakis, C. et al. Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 124, 527–531 (1998). https://doi.org/10.1007/s004320050210
Issue Date:
DOI: https://doi.org/10.1007/s004320050210